estriol has been researched along with Vaginal Diseases in 34 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
Vaginal Diseases: Pathological processes of the VAGINA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA)." | 9.27 | Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. ( Cruz, VL; Fernandes, CE; Fonseca, FLA; Pompei, LM; Santiago, LHS; Steiner, ML; Strufaldi, R; Wajsfeld, T, 2018) |
| "03 mg estriol-lactobacilli combination (Gynoflor(®)) was superior to placebo with respect to changes in VMI after the 12-day initial therapy, and the maintenance therapy of two tablets weekly was sufficient to prevent the relapse of vaginal atrophy." | 9.17 | Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. ( Chaikittisilpa, S; Grob, P; Jaisamrarn, U; Prasauskas, V; Taechakraichana, N; Triratanachat, S, 2013) |
| "The aim of the study was to confirm the superior efficacy of estriol containing pessaries compared to placebo in the treatment of vaginal atrophy." | 9.16 | Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. ( Fielder, K; Fischer, T; Griesser, H; Skonietzki, S; Suesskind, M, 2012) |
| "005% Estriol vaginal gel, a new formulation providing an ultra low dose of estriol per application, was shown to be safe and effective in the treatment of postmenopausal vaginal atrophy." | 9.16 | The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. ( Cano, A; Castellanos, E; del Prado, JM; Delgado, JL; Estévez, J; Ferrer, J; Gallo, JL; Guinot, M; Moral, E; Nieto, C; Usandizaga, R, 2012) |
| "005% oestriol vaginal gel on dyspareunia in postmenopausal women within the first 2 weeks of treatment." | 8.12 | Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study. ( Cuerva, MJ; González, SP; Lazaro-Carrasco De La Fuente, J; Lopez, FJ; Nieto, C, 2022) |
| "We investigated the effect of a combination of vaginal ultra-low-dose estriol with lactobacilli on the sexual functioning domain of quality of life during the treatment of breast cancer survivors on an aromatase inhibitor with vaginal atrophy." | 7.81 | Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Mögele, M; Neven, P; Ortmann, O; Prasauskas, V, 2015) |
| " Vaginal pH measurement, subjective symptoms, and objective signs assessment of VVA, endometrial thickness and adverse events (AE) were recorded." | 6.94 | Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment. ( Amar, ID; Cipolla, C; Ingravalle, F; Lanzone, A; Ricciardi, W; Scambia, G; Tagliaferri, V; Villa, P, 2020) |
| " Adverse events and discomfort encountered during the procedure were also assessed." | 5.72 | Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy. ( Alvisi, S; Baldassarre, M; Lami, A; Lenzi, J; Mancini, I; Meriggiola, MC; Seracchioli, R, 2022) |
| "The aim of the study was to evaluate efficacy of fractional CO2 vaginal laser treatment (Laser, L) and compare it to local estrogen therapy (Estriol, E) and the combination of both treatments (Laser + Estriol, LE) in the treatment of vulvovaginal atrophy (VVA)." | 5.27 | Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women. ( Cruz, VL; Fernandes, CE; Fonseca, FLA; Pompei, LM; Santiago, LHS; Steiner, ML; Strufaldi, R; Wajsfeld, T, 2018) |
| "Estriol 20 and 50 μg/g formulations, while showing a comparable capacity for reversing vaginal atrophy, present a highly favorable safety profile, producing a very low systemic absorption of estriol and significantly lower than that of Ovestinon®." | 5.22 | Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women. ( Delgado, JL; Estevez, J; Loprete, L; Moscoso Del Prado, J; Nieto Magro, C; Radicioni, M, 2016) |
| "03 mg estriol-lactobacilli combination (Gynoflor(®)) was superior to placebo with respect to changes in VMI after the 12-day initial therapy, and the maintenance therapy of two tablets weekly was sufficient to prevent the relapse of vaginal atrophy." | 5.17 | Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. ( Chaikittisilpa, S; Grob, P; Jaisamrarn, U; Prasauskas, V; Taechakraichana, N; Triratanachat, S, 2013) |
| "The aim of the study was to confirm the superior efficacy of estriol containing pessaries compared to placebo in the treatment of vaginal atrophy." | 5.16 | Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. ( Fielder, K; Fischer, T; Griesser, H; Skonietzki, S; Suesskind, M, 2012) |
| "005% Estriol vaginal gel, a new formulation providing an ultra low dose of estriol per application, was shown to be safe and effective in the treatment of postmenopausal vaginal atrophy." | 5.16 | The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. ( Cano, A; Castellanos, E; del Prado, JM; Delgado, JL; Estévez, J; Ferrer, J; Gallo, JL; Guinot, M; Moral, E; Nieto, C; Usandizaga, R, 2012) |
| "005% oestriol vaginal gel on dyspareunia in postmenopausal women within the first 2 weeks of treatment." | 4.12 | Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study. ( Cuerva, MJ; González, SP; Lazaro-Carrasco De La Fuente, J; Lopez, FJ; Nieto, C, 2022) |
| "We investigated the effect of a combination of vaginal ultra-low-dose estriol with lactobacilli on the sexual functioning domain of quality of life during the treatment of breast cancer survivors on an aromatase inhibitor with vaginal atrophy." | 3.81 | Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. ( Bellen, G; Buchholz, S; Donders, G; Grob, P; Lintermans, A; Mögele, M; Neven, P; Ortmann, O; Prasauskas, V, 2015) |
| " Vaginal pH measurement, subjective symptoms, and objective signs assessment of VVA, endometrial thickness and adverse events (AE) were recorded." | 2.94 | Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment. ( Amar, ID; Cipolla, C; Ingravalle, F; Lanzone, A; Ricciardi, W; Scambia, G; Tagliaferri, V; Villa, P, 2020) |
| "To evaluate the effectiveness of live lactobacilli in combination with low dose oestriol for restoration of the vaginal flora after anti-infective treatment." | 2.71 | The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. ( Grob, P; Kaiser, R; Ozkinay, E; Terek, MC; Tuncay, G; Yayci, M, 2005) |
| "The intensified treatment of breast cancer improves survival but has a price in terms of side-effects." | 2.48 | The management of menopausal symptoms in breast cancer survivors: case-based approach. ( de Bock, GH; Lammerink, EA; Mourits, MJ; Schröder, CP, 2012) |
| " Adverse events and discomfort encountered during the procedure were also assessed." | 1.72 | Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy. ( Alvisi, S; Baldassarre, M; Lami, A; Lenzi, J; Mancini, I; Meriggiola, MC; Seracchioli, R, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (26.47) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.82) | 29.6817 |
| 2010's | 16 (47.06) | 24.3611 |
| 2020's | 6 (17.65) | 2.80 |
| Authors | Studies |
|---|---|
| Alvisi, S | 1 |
| Lami, A | 1 |
| Baldassarre, M | 1 |
| Lenzi, J | 1 |
| Mancini, I | 1 |
| Seracchioli, R | 1 |
| Meriggiola, MC | 1 |
| Garcia de Arriba, S | 1 |
| Grüntkemeier, L | 1 |
| Häuser, M | 1 |
| May, TW | 1 |
| Masur, C | 1 |
| Stute, P | 2 |
| Cuerva, MJ | 1 |
| González, SP | 1 |
| Lazaro-Carrasco De La Fuente, J | 1 |
| Lopez, FJ | 1 |
| Nieto, C | 3 |
| Donders, GGG | 1 |
| Donders, FHWV | 1 |
| Comini, ACM | 1 |
| Carvalho, BM | 1 |
| Moreira, MJB | 1 |
| Reis, PCA | 1 |
| Colapietro, L | 1 |
| Northern, J | 1 |
| Batalini, F | 1 |
| Villa, P | 1 |
| Tagliaferri, V | 1 |
| Amar, ID | 1 |
| Cipolla, C | 1 |
| Ingravalle, F | 1 |
| Scambia, G | 1 |
| Ricciardi, W | 1 |
| Lanzone, A | 1 |
| Caruso, S | 2 |
| Cianci, S | 2 |
| Vitale, SG | 1 |
| Matarazzo, MG | 1 |
| Amore, FF | 2 |
| Cianci, A | 2 |
| Cruz, VL | 1 |
| Steiner, ML | 1 |
| Pompei, LM | 1 |
| Strufaldi, R | 1 |
| Fonseca, FLA | 1 |
| Santiago, LHS | 1 |
| Wajsfeld, T | 1 |
| Fernandes, CE | 1 |
| Mitchell, CM | 1 |
| Mueck, AO | 1 |
| Ruan, X | 1 |
| Prasauskas, V | 3 |
| Grob, P | 4 |
| Ortmann, O | 2 |
| Buchholz, S | 1 |
| Mögele, M | 1 |
| Lintermans, A | 1 |
| Bellen, G | 1 |
| Neven, P | 1 |
| Donders, G | 1 |
| Ventura, B | 1 |
| Bambili, E | 1 |
| Spadola, S | 1 |
| Delgado, JL | 3 |
| Estevez, J | 3 |
| Radicioni, M | 1 |
| Loprete, L | 1 |
| Moscoso Del Prado, J | 1 |
| Nieto Magro, C | 1 |
| Weber, MA | 1 |
| Lim, V | 1 |
| Oryszczyn, J | 1 |
| Te West, N | 1 |
| Souget, J | 1 |
| Jeffery, S | 1 |
| Roovers, JP | 1 |
| Moore, KH | 1 |
| Griesser, H | 1 |
| Skonietzki, S | 1 |
| Fischer, T | 1 |
| Fielder, K | 1 |
| Suesskind, M | 1 |
| López-Belmonte, J | 1 |
| del Prado, JM | 2 |
| Lammerink, EA | 1 |
| de Bock, GH | 1 |
| Schröder, CP | 1 |
| Mourits, MJ | 1 |
| Cano, A | 1 |
| Usandizaga, R | 1 |
| Gallo, JL | 1 |
| Guinot, M | 1 |
| Castellanos, E | 1 |
| Moral, E | 1 |
| Ferrer, J | 1 |
| Mariani, L | 1 |
| Gadducci, A | 1 |
| Vizza, E | 1 |
| Tomao, S | 1 |
| Vici, P | 1 |
| Cusack, L | 1 |
| Brennan, M | 1 |
| Baber, R | 1 |
| Boyle, F | 1 |
| Jaisamrarn, U | 1 |
| Triratanachat, S | 1 |
| Chaikittisilpa, S | 1 |
| Taechakraichana, N | 1 |
| Palacios, S | 1 |
| Castelo-Branco, C | 1 |
| Cancelo, MJ | 1 |
| Vázquez, F | 1 |
| Ozkinay, E | 1 |
| Terek, MC | 1 |
| Yayci, M | 1 |
| Kaiser, R | 1 |
| Tuncay, G | 1 |
| Cismigiu, F | 1 |
| Gomer, M | 1 |
| Heraud, M | 1 |
| Michalas, S | 1 |
| Papandrikos, A | 1 |
| Koutselini, E | 1 |
| Tzingounis, V | 1 |
| Dugal, R | 1 |
| Hesla, K | 1 |
| Sørdal, T | 1 |
| Aase, KH | 1 |
| Lilleeidet, O | 1 |
| Wickstrøm, E | 1 |
| Jansson, I | 1 |
| Okuyama, M | 1 |
| Bachmann, FF | 1 |
| Patt, V | 1 |
| Korte, W | 1 |
| Cohen, L | 1 |
| Lauritzen, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Laser Therapy on Vaginal Tissue at Biomechanical, Histological and Molecular Level in Women With Pelvic Organ Prolapse - Pilot Study[NCT05898191] | 15 participants (Actual) | Interventional | 2019-02-01 | Active, not recruiting | |||
| Effects on Vaginal Health and Quality of Life in Postmenopausal Women Using Ultra Low Topic Estriol Before Vaginal Surgery for Pelvic Statics Disorders[NCT02906111] | Phase 4 | 88 participants (Anticipated) | Interventional | 2016-11-30 | Not yet recruiting | ||
| Randomized, Double-blind, Placebo-controlled, Parallel Groups, Multicentre Study, to Determine Efficacy and Safety of a Low Concentration Estriol (ITFE-2026 0.005%) by Vaginal Route in the Treatment of Postmenopausal Vaginal Atrophy.[NCT04574999] | Phase 3 | 167 participants (Actual) | Interventional | 2008-01-25 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Maturation value (MV) is a cytologic parameter indicative of the degree of atrophy of the vaginal mucosa.~This variable is a quantitative parameter indicative of the cytological status of the vaginal epithelium. The number of parabasal, intermediate and superficial cells was calculated from 300 consecutive cells of the samples of vaginal cytology, and the percentages of each type of cells obtained. The Maturation Value was obtained based on the following formula: 0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial). The higher the value, the higher the maturation degree." (NCT04574999)
Timeframe: At week 12/Early withdrawal
| Intervention | vaginal health index (Mean) |
|---|---|
| 0.005% Estriol Group | 26.9 |
| Placebo Group | 3.2 |
As a consequence of reduced estrogen levels, the vaginal mucosa occurs loses its rugosity, its thickness decreases, and it becomes pale and friable. The production of glycogen decreases, which determines vaginal pH alkalinization. (NCT04574999)
Timeframe: At week 12 /early withdrawal
| Intervention | pH units (Mean) |
|---|---|
| 0.005% Estriol Group | -1.2 |
| Placebo Group | -0.4 |
"Maturation value (MV) is a cytologic parameter indicative of the degree of atrophy of the vaginal mucosa.~This variable is a quantitative parameter indicative of the cytological status of the vaginal epithelium. The number of parabasal, intermediate and superficial cells was calculated from 300 consecutive cells of the samples of vaginal cytology, and the percentages of each type of cells obtained. The Maturation Value was obtained based on the following formula: 0.2 x (% parabasal) + 0.6 x (% intermediate) + 1.0 x (% superficial). The higher the value, the higher the maturation degree." (NCT04574999)
Timeframe: At week 3/ early withdrawal
| Intervention | vaginal health index (Mean) |
|---|---|
| 0.005% Estriol Group | 37.9 |
| Placebo Group | 3.6 |
As a consequence of reduced estrogen levels, the vaginal mucosa occurs loses its rugosity, its thickness decreases, and it becomes pale and friable. The production of glycogen decreases, which determines vaginal pH alkalinization. (NCT04574999)
Timeframe: At week 3 / early withdrawal
| Intervention | pH units (Mean) |
|---|---|
| 0.005% Estriol Group | -1.4 |
| Placebo Group | -0.3 |
"Signs and symptoms of vaginal atrophy are: vaginal dryness, pruritus or itching, burning, dyspareunia, dysuria.~For each of these symptoms the subject indicates one the following status: present, absent, missing.~Symptoms of vaginal atrophy were scored by the patients in a numeric scale from 0 to 3, as shown below:~0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient's~The symptom is very irritating and severe in intensity~Signs of vaginal atrophy were evaluated by the investigator and scored on a numerical scale as shown below:~0 Absence. The symptom is not present~The sign is present and is considered a mild alteration~The sign is present and is considered a moderate alteration~The sign is present and is considered a severe alteration" (NCT04574999)
Timeframe: At baseline and at 12 weeks / early withdrawal
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaginal dryness - Baseline - present | Vaginal dryness - Baseline - absent | Vaginal dryness - Baseline - missing | Vaginal dryness - week 12 - present | Vaginal dryness - week 12 - absent | Vaginal dryness - week 12 - missing | Pruritus - Baseline - present | Pruritus - Baseline - absent | Pruritus - Baseline - missing | Pruritus - week 12 - present | Pruritus - week 12 - absent | Pruritus - week 12 - missing | Burning - Baseline - present | Burning - Baseline - absent | Burning - Baseline - missing | Burning - week 12 - present | Burning - week 12 - absent | Burning - week 12 - missing | Dyspareunia - Baseline - present | Dyspareunia - Baseline - absent | Dyspareunia - Baseline - missing | Dyspareunia - week 12 - present | Dyspareunia - week 12 - absent | Dyspareunia - week 12 - missing | Dysuria - Baseline - present | Dysuria - Baseline - absent | Dysuria - Baseline - missing | Dysuria - week 12 - present | Dysuria - week 12 - absent | Dysuria - week 12 - missing | |
| 0.005% Estriol Group | 114 | 0 | 0 | 71 | 39 | 3 | 55 | 59 | 0 | 18 | 92 | 3 | 48 | 66 | 0 | 14 | 96 | 3 | 101 | 11 | 2 | 51 | 56 | 6 | 27 | 85 | 2 | 2 | 108 | 3 |
| Placebo Group | 53 | 0 | 0 | 39 | 12 | 2 | 29 | 24 | 0 | 11 | 40 | 2 | 18 | 35 | 0 | 11 | 40 | 2 | 48 | 5 | 0 | 24 | 25 | 4 | 14 | 39 | 0 | 7 | 44 | 2 |
"Signs and symptoms of vaginal atrophy are: vaginal dryness, pruritus or itching, burning, dyspareunia, dysuria.~For each of these symptoms the subject indicates one the following status: present, absent, missing.~Symptoms of vaginal atrophy were scored by the patients in a numeric scale from 0 to 3, as shown below:~0 Absence. The symptom is not present~The symptom is of mild intensity, without interfering in the patient's activity~The symptom is of moderate intensity, causing obvious discomfort to the patient's~The symptom is very irritating and severe in intensity~Signs of vaginal atrophy were evaluated by the investigator and scored on a numerical scale as shown below:~0 Absence. The symptom is not present~The sign is present and is considered a mild alteration~The sign is present and is considered a moderate alteration~The sign is present and is considered a severe alteration" (NCT04574999)
Timeframe: At 3 weeks
| Intervention | Participants (Count of Participants) | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vaginal dryness - Baseline - present | Vaginal dryness - Baseline - absent | Vaginal dryness - Baseline - missing | Vaginal dryness - week 3 - present | Vaginal dryness - week 3 - absent | Vaginal dryness - week 3 - missing | Pruritus - Baseline - present | Pruritus - Baseline - absent | Pruritus - Baseline - missing | Pruritus - week 3 - present | Pruritus - week 3 - absent | Pruritus - week 3 - missing | Burning - Baseline - present | Burning - Baseline - absent | Burning - Baseline - missing | Burning - week 3 - present | Burning - week 3 - absent | Burning - week 3 - missing | Dyspareunia - Baseline - present | Dyspareunia - Baseline - absent | Dyspareunia - Baseline - missing | Dyspareunia - week 3 - present | Dyspareunia - week 3 - absent | Dyspareunia - week 3 - missing | Dysuria - Baseline - present | Dysuria - Baseline - absent | Dysuria - Baseline - missing | Dysuria - week 3 - present | Dysuria - week 3 - absent | Dysuria - week 3 - missing | |
| 0.005% Estriol Group | 114 | 0 | 0 | 84 | 21 | 0 | 55 | 59 | 0 | 21 | 84 | 0 | 48 | 66 | 0 | 22 | 83 | 0 | 101 | 11 | 2 | 60 | 40 | 5 | 27 | 85 | 2 | 7 | 98 | 0 |
| Placebo Group | 53 | 0 | 0 | 43 | 8 | 0 | 29 | 24 | 0 | 13 | 38 | 0 | 18 | 35 | 0 | 11 | 40 | 0 | 48 | 5 | 0 | 32 | 16 | 3 | 14 | 39 | 0 | 5 | 46 | 0 |
4 reviews available for estriol and Vaginal Diseases
| Article | Year |
|---|---|
New developments in the management of vulvovaginal atrophy: a comprehensive overview.
Topics: Atrophy; Estriol; Estrogens; Female; Humans; Selective Estrogen Receptor Modulators; Vagina; Vaginal | 2023 |
Safety and Serum Estradiol Levels in Hormonal Treatments for Vulvovaginal Atrophy in Breast Cancer Survivors: A Systematic Review and Meta-Analysis.
Topics: Atrophy; Breast Neoplasms; Cancer Survivors; Estradiol; Estriol; Estrogens; Female; Humans; Neoplasm | 2023 |
Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review.
Topics: Administration, Intravaginal; Atrophy; Combined Modality Therapy; Estriol; Female; Humans; Lactobaci | 2018 |
The management of menopausal symptoms in breast cancer survivors: case-based approach.
Topics: Acupuncture Therapy; Breast Neoplasms; Estriol; Estrogen Replacement Therapy; Female; Hot Flashes; H | 2012 |
14 trials available for estriol and Vaginal Diseases
| Article | Year |
|---|---|
Vaginal hormone-free moisturising cream is not inferior to an estriol cream for treating symptoms of vulvovaginal atrophy: Prospective, randomised study.
Topics: Administration, Intravaginal; Atrophy; Dyspareunia; Estriol; Female; Humans; Male; Postmenopause; Pr | 2022 |
Local ultra-low-dose estriol gel treatment of vulvo-vaginal atrophy: efficacy and safety of long-term treatment.
Topics: Administration, Topical; Adult; Aged; Atrophy; Dose-Response Relationship, Drug; Drug Administration | 2020 |
Effects of ultralow topical estriol dose on vaginal health and quality of life in postmenopausal women who underwent surgical treatment for pelvic organ prolapse.
Topics: Atrophy; Estriol; Female; Humans; Interviews as Topic; Middle Aged; Pelvic Organ Prolapse; Postmenop | 2017 |
Randomized, double-blind, placebo-controlled clinical trial for evaluating the efficacy of fractional CO2 laser compared with topical estriol in the treatment of vaginal atrophy in postmenopausal women.
Topics: Administration, Intravaginal; Aged; Atrophy; Double-Blind Method; Estriol; Female; Humans; Lasers, G | 2018 |
Pharmacokinetics and preliminary efficacy of two vaginal gel formulations of ultra-low-dose estriol in postmenopausal women.
Topics: Administration, Intravaginal; Aged; Atrophy; Biological Availability; Estriol; Female; Gels; Humans; | 2016 |
Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol.
Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Double-Blind Method; Estriol; | 2012 |
The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study.
Topics: Atrophy; Double-Blind Method; Estriol; Estrogens; Female; Humans; Hydrogen-Ion Concentration; Middle | 2012 |
Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy.
Topics: Administration, Intravaginal; Atrophy; Double-Blind Method; Epithelium; Estriol; Female; Humans; Lac | 2013 |
Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
Topics: Administration, Cutaneous; Administration, Intravaginal; Adult; Atrophy; Colposcopy; Contraceptive A | 2005 |
The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections.
Topics: Administration, Intravaginal; Adolescent; Adult; Aged; Anti-Infective Agents; Combined Modality Ther | 2005 |
[Experimentation with a new product: FH 123 A].
Topics: Administration, Intravaginal; Capsules; Estriol; Female; Humans; Progesterone; Vaginal Diseases | 1973 |
Local therapy of atrophic vaginal conditions with oestriol suppositories.
Topics: Aged; Atrophy; Clinical Trials as Topic; Estriol; Female; Humans; Menopause; Middle Aged; Suppositor | 1980 |
Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy.
Topics: Administration, Intravaginal; Aged; Atrophy; Drug Administration Schedule; Estradiol; Estriol; Femal | 2000 |
[Experience with an injectionable estriol Depot preparation. (Gynaesan pro injectione)].
Topics: Atrophy; Estriol; Female; Genital Diseases, Female; Humans; Injections, Intramuscular; Leukoplakia; | 1968 |
16 other studies available for estriol and Vaginal Diseases
| Article | Year |
|---|---|
Short-Term Efficacy and Safety of Non-Ablative Laser Treatment Alone or with Estriol or Moisturizers in Postmenopausal Women with Vulvovaginal Atrophy.
Topics: Atrophy; Carbon Dioxide; Estriol; Female; Humans; Pain; Postmenopause; Pruritus; Quality of Life; Tr | 2022 |
Effect of oestriol gel on dyspareunia in postmenopausal women in 2 weeks of treatment: a pilot study.
Topics: Dyspareunia; Estriol; Female; Humans; Pilot Projects; Postmenopause; Prospective Studies; Vagina; Va | 2022 |
Seeing the light: the need for randomized trials of vaginal laser in postmenopausal women.
Topics: Atrophy; Double-Blind Method; Estriol; Female; Humans; Lasers, Gas; Postmenopause; Randomized Contro | 2018 |
Is vaginal hyaluronic acid as effective as vaginal estriol for vaginal dryness relief?
Topics: Administration, Intravaginal; Adult; Aged; Dyspareunia; Estriol; Female; Humans; Hyaluronic Acid; Mi | 2013 |
Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer.
Topics: Administration, Intravaginal; Aromatase Inhibitors; Atrophy; Breast Neoplasms; Combined Modality The | 2015 |
Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel.
Topics: Administration, Intravaginal; Atrophy; Case-Control Studies; Estriol; Female; Humans; Middle Aged; P | 2016 |
The Effect of Vaginal Oestriol Cream on Subjective and Objective Symptoms of Stress Urinary Incontinence and Vaginal Atrophy: An International Multi-Centre Pilot Study.
Topics: Administration, Intravaginal; Aged; Atrophy; Estriol; Female; Humans; Hydrogen-Ion Concentration; Mi | 2017 |
Comparative uterine effects on ovariectomized rats after repeated treatment with different vaginal estrogen formulations.
Topics: Administration, Intravaginal; Animals; Atrophy; Endometrium; Estradiol; Estriol; Estrogens; Female; | 2012 |
Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
Topics: Administration, Intravaginal; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Atrophy; Breast | 2013 |
Menopausal symptoms in breast cancer survivors: management update.
Topics: Aged; Antineoplastic Agents; Anxiety; Breast Neoplasms; Clinical Trials as Topic; Depression; Estrio | 2013 |
Gynaecological problems in elderly women. Practical clinical aspects, treatment, care programme.
Topics: Aged; Aged, 80 and over; Estriol; Female; Genital Diseases, Female; Humans; Middle Aged; Patient Car | 1987 |
[Examination of the side effects of estriol preparations].
Topics: Adult; Drug Hypersensitivity; Estriol; Female; Genital Diseases, Female; Humans; Menstruation Distur | 1972 |
[Treatment of menopausal complants with polyoestriol-phosphate. Experiences with Gynäsan injections].
Topics: Aged; Atrophy; Biopsy; Blood Circulation; Body Temperature Regulation; Estriol; Female; Humans; Meno | 1971 |
[Principles of estriol therapy].
Topics: Body Temperature; Endometrium; Estriol; Female; Humans; Urinary Bladder Diseases; Vagina; Vaginal Di | 1971 |
Selective action on the lower genital tract with a weak oestrogen (Pentovis).
Topics: Climacteric; Epithelium; Estriol; Female; Genitalia, Female; Humans; Middle Aged; Vaginal Diseases | 1968 |
[Ovestin. Oestriol, natural female hormone with local impact].
Topics: Estriol; Female; Humans; Vaginal Diseases | 1966 |